Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Neurol Neuroimmunol Neuroinflamm · 2015 · PMC4396529 · PMID 25884010

Europe PMC DOI

hedged sentence

0.2200

closest p · 4.4× alpha

0.2200

boldest claim

The sentences

did not reach statistical significancep = 0.22not close (p > 0.1)

In the high-dose group, 25% of patients did not progress over the 6-month treatment period ( figure 3A ), which is more than 2 times greater than the percentage in the placebo group (11%), although it did not reach statistical significance ( p = 0.22).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.